newsfilter
← Latest News
Business Wire·

Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors appro